1-(2,6-二氯-4-甲氧基苯基)靛红 | 320778-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-(2,6-二氯-4-甲氧基苯基)靛红
• 中文别名: 1-（2,6-二氯-4-甲氧基苯基）-1H-吲哚-2,3-二酮-d4
• 英文名称: 1-(2,6-dichloro-4-methoxyphenyl) isatin
• 英文别名: 1-(2,6-Dichloro-4-methoxyphenyl)indole-2,3-dione
• CAS: 320778-04-9
• 化学式: C₁₅H₉Cl₂NO₃
• 分子量: 322.147
• InChiKey: WAWQBOFXWDOYMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2,6-二氯-4-甲氧基苯基)靛红 在 氢氧化钾 、 sodium hydroxide 、 sodium methylate 、 吡啶盐酸盐 、 一水合肼 作用下， 以 乙醇 、 乙二醇甲醚 、 水 、 正丁醇 为溶剂， 反应 28.17h， 生成 4’-羟基双氯芬酸
  参考文献：
  名称：

  Synthesis and quantitative structure-activity relationships of diclofenac analogs

  摘要：

  The synthesis of a series of 2-anilinophenylacetic acids, close analogues of diclofenac, is described. These compounds were tested in two models used for evaluating the activity of nonsteroidal antiinflammatory drugs (NSAID's), inhibition of cyclooxygenase enzyme activity in vitro, and adjuvant-induced arthritis (AdA) in rats. Statistically significant correlations were found between the inhibitory activities of the compounds in these two models, indicating that cyclooxygenase inhibition seems to be the underlying mechanism for the antiinflammatory activity of these compounds. Quantitative structure-activity relationship (QSAR) analysis revealed that the crucial parameters for activity in both models were the lipophilicity and the angle of twist between the two phenyl rings. Optimal activities were associated with halogen or alkyl substituents in both ortho positions of the anilino ring. Compounds with OH groups in addition to two ortho substituents or compounds with only one or no ortho substituents were less active.

  DOI：

  10.1021/jm00171a008
• 作为产物：
  描述：

  (2,6-二氯-4-甲氧基苯基)苯胺 在 三氯化铝 作用下， 以 苯 为溶剂， 反应 22.0h， 生成 1-(2,6-二氯-4-甲氧基苯基)靛红
  参考文献：
  名称：

  Synthesis and quantitative structure-activity relationships of diclofenac analogs

  摘要：

  The synthesis of a series of 2-anilinophenylacetic acids, close analogues of diclofenac, is described. These compounds were tested in two models used for evaluating the activity of nonsteroidal antiinflammatory drugs (NSAID's), inhibition of cyclooxygenase enzyme activity in vitro, and adjuvant-induced arthritis (AdA) in rats. Statistically significant correlations were found between the inhibitory activities of the compounds in these two models, indicating that cyclooxygenase inhibition seems to be the underlying mechanism for the antiinflammatory activity of these compounds. Quantitative structure-activity relationship (QSAR) analysis revealed that the crucial parameters for activity in both models were the lipophilicity and the angle of twist between the two phenyl rings. Optimal activities were associated with halogen or alkyl substituents in both ortho positions of the anilino ring. Compounds with OH groups in addition to two ortho substituents or compounds with only one or no ortho substituents were less active.

  DOI：

  10.1021/jm00171a008

文献信息

• Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
  申请人：——

  公开号：US20010034359A1

  公开（公告）日：2001-10-25

  The present invention is directed to compositions that inhibit the nonenzymatic glycation of albumin, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies.

  本发明涉及抑制白蛋白非酶促糖基化的组合物，并使用抑制白蛋白糖基化的化合物治疗糖基化相关病理的方法。
• ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES
  申请人：EXOCELL, INC.

  公开号：EP1242069A2

  公开（公告）日：2002-09-25
• US6355680B1
  申请人：——

  公开号：US6355680B1

  公开（公告）日：2002-03-12
• US6552077B2
  申请人：——

  公开号：US6552077B2

  公开（公告）日：2003-04-22
• [EN] ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES<br/>[FR] COMPOSES LIANT L'ALBUMINE QUI EMPECHENT LA GLYCATION NON ENZYMATIQUE ET QUI PEUVENT ETRE UTILISES DANS LE TRAITEMENT DE PATHOLOGIES LIEES A LA GLYCATION
  申请人：EXOCELL INC

  公开号：WO2001003684A2

  公开（公告）日：2001-01-18

  The present invention is directed to compositions, comprising substituted 2(pheryl amino) pheryl acetic acid compounds, that inhibit the nonenzymatic glycation of albumin, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies including renol vascular dysfunction.